Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Cross‐linking/mass spectrometry for studying protein structures and protein–protein interactions: where are we now and where should we go from here?
A Sinz - Angewandte Chemie International Edition, 2018 - Wiley Online Library
Structural mass spectrometry (MS) is gaining increasing importance for deriving valuable
three‐dimensional structural information on proteins and protein complexes, and it …
three‐dimensional structural information on proteins and protein complexes, and it …
[HTML][HTML] Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Hepatocarcinogenesis is a multistep process mainly associated with persistent infection with …
Hepatocarcinogenesis is a multistep process mainly associated with persistent infection with …
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
N Mohell, J Alfredsson, Å Fransson, M Uustalu… - Cell death & …, 2015 - nature.com
Two main causes of platinum resistance are mutation in the tumor suppressor gene TP53
and drug-induced increase in intracellular glutathione concentration. Mutations in TP53 …
and drug-induced increase in intracellular glutathione concentration. Mutations in TP53 …
[HTML][HTML] Structural and drug targeting insights on mutant p53
AS Gomes, H Ramos, A Inga, E Sousa, L Saraiva - Cancers, 2021 - mdpi.com
Simple Summary The tumor suppressor protein p53 is frequently mutated in human cancers,
and its reactivation represents an encouraging hope for precision anticancer therapy …
and its reactivation represents an encouraging hope for precision anticancer therapy …
Mesoscopic protein-rich clusters host the nucleation of mutant p53 amyloid fibrils
The protein p53 is a crucial tumor suppressor, often called “the guardian of the genome”;
however, mutations transform p53 into a powerful cancer promoter. The oncogenic capacity …
however, mutations transform p53 into a powerful cancer promoter. The oncogenic capacity …
Design of a molecular support for cryo-EM structure determination
Despite the recent rapid progress in cryo-electron microscopy (cryo-EM), there still exist
ample opportunities for improvement in sample preparation. Macromolecular complexes …
ample opportunities for improvement in sample preparation. Macromolecular complexes …
The first zero‐length mass spectrometry‐cleavable cross‐linker for protein structure analysis
C Hage, C Iacobucci, A Rehkamp… - Angewandte Chemie …, 2017 - Wiley Online Library
Combining the properties of a zero‐length cross‐linker with cleavability by tandem mass
spectrometry (MS/MS) poses great advantages for protein structure analysis using the cross …
spectrometry (MS/MS) poses great advantages for protein structure analysis using the cross …
Mdm2: open questions
M Dobbelstein, AJ Levine - Cancer Science, 2020 - Wiley Online Library
The Mdm2 oncoprotein and its association with p53 were discovered 30 years ago, and a
cornucopia of activities and regulatory pathways have been associated with it. In this review …
cornucopia of activities and regulatory pathways have been associated with it. In this review …
Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage
Y Zerdoumi, R Lanos, S Raad… - Human molecular …, 2017 - academic.oup.com
Abstract Li-Fraumeni Syndrome (LFS) results from heterozygous germline mutations of
TP53, encoding a key transcriptional factor activated in response to DNA damage. We have …
TP53, encoding a key transcriptional factor activated in response to DNA damage. We have …
Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor
p53 is a key protein that participates in cell-cycle control, and its malfunction can lead to
cancer. This tumour suppressor protein has three main domains; the N-terminal …
cancer. This tumour suppressor protein has three main domains; the N-terminal …